<DOC>
	<DOCNO>NCT02532712</DOCNO>
	<brief_summary>This study Dose block-randomized , Double-blind , Placebo-controlled , Single Multiple Ascending Dose Escalation , Phase I clinical trial ass safety , tolerability pharmacokinetics single-dose multiple-dose oral administration investigational product , EC-18 ( study drug ) healthy adult male volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability PK EC-18 After Oral Administration Healthy Volunteers</brief_title>
	<detailed_description>In vitro vivo efficacy study clinical trial show EC-18 mode action improve neutropenia promote neutrophil production hematopoietic stem cell time , efficiently control STAT6/Complement 3 ( C3 ) , suggest potential develop orally administer new drug treatment neutropenia result decrease neutrophil cause administration anticancer agent . This study Dose block-randomized , Double-blind , Placebo-controlled , Single Multiple Ascending Dose Escalation , Phase I clinical trial ass safety , tolerability pharmacokinetics single-dose multiple-dose oral administration investigational product , EC-18 ( study drug ) healthy adult male volunteer .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Healthy adult male age 19 45 year , inclusive , time provide informed consent form Body weight ≥ 50 kg , calculate BMI range 18.5 kg/m2 ≤ BMI &lt; 25.0 kg/m2 ☞ BMI ( body mass index ) = Body weight ( kg ) / [ height ( ) ] 2 No inherited chronic disease pathologic symptom finding internal examination Eligible subject base finding clinical laboratory test , hematology , blood chemistry , urinalysis immunoserology , ECG , conduct responsible doctor depend characteristic drug Written consent voluntary decision participation compliance precaution fully inform completely understanding trial Consent practice medically acceptable contraception trial Hypersensitivity drug contain ingredient investigational product ( EC18 ) similar ingredient ( e.g. , deer antler ) drug ( e.g. , aspirin , antibiotic ) medical history clinically significant hypersensitivity Active infection chronic local infection base screening test inquiry , verifiable medical record Serious infection require hospitalization use antibiotic within 30 day prior first dose investigational product , base inquiry verifiable medical record Presence clinically significant hepatic , renal , gastrointestinal , respiratory , musculoskeletal , endocrine , nervous , blood , cardiovascular , urogenital , psychiatric disorder prior history ( 1 ) Presenting tuberculosis prior history tuberculosis ( 2 ) positive result QuantiFERON® TB Gold Tube Assay conduct due contact tuberculosis patient within past 3 month sign symptom suspect tuberculosis Prior history gastrointestinal disorder ( e.g. , Crohn 's disease , ulcer ) surgery ( except simple appendectomy hernia surgery ) may affect drug absorption , etc .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>EC-18</keyword>
	<keyword>Hematology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Neutropenia</keyword>
</DOC>